AngioDynamics (ANGO) Q1 2026 earnings summary

Executive summary

• Achieved 12.2% year-over-year revenue growth to $75.7 million in Q1 FY26, led by 26.1% Med Tech growth and 2.3% Med Device growth.

• Med Tech segment sales reached $35.3 million, marking the fourth consecutive quarter of over 20% growth.

• Mechanical thrombectomy business grew over 40% year-over-year, and NanoKnife revenue increased 26.7%, driven by prostate indication adoption.

• Gross margin improved to 55.3%, with Med Tech at 62.2% and Med Device at 49.3%.

• Ended the quarter with $38.8 million in cash and zero debt, providing financial flexibility.

Financial highlights

• Q1 FY26 net sales were $75.7 million, up from $67.5 million in Q1 FY25.

• Adjusted net loss for Q1 FY26 was $4.2 million (loss per share $0.10), improved from $4.4 million (loss per share $0.11) in Q1 FY25; GAAP net loss was $10.9 million (loss per share $0.26).

• Adjusted EBITDA turned positive at $2.2 million, up from a loss of $152,000 in the prior year.

• Cash utilization for the quarter was $17.1 million, with cash and cash equivalents at $38.8 million.

• No outstanding debt and a $25 million revolving credit facility remains undrawn.

Outlook and guidance

• FY26 net sales guidance raised to $308–$313 million (5–7% growth over FY25).

• Med Tech net sales expected to grow 14–16%; Med Device sales to remain flat.

• Gross margin guidance maintained at 53.5–55.5%, inclusive of $4–$6 million tariff impact.

• Adjusted EBITDA guidance increased to $6–$10 million; adjusted loss per share improved to $0.33–$0.23.

• Expects to be cash flow positive for full FY26.